根据 位华尔街分析师的预测,Virax Biolabs Group Ltd 的收入预期范围从 $ 到 $
Virax Biolabs Group Ltd 的盈利质量评分是多少?
Virax Biolabs Group Ltd 的盈利质量评分为 B/32.836884。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Virax Biolabs Group Ltd 何时发布财报?
Virax Biolabs Group Ltd 的下一份财报预计在 发布
Virax Biolabs Group Ltd 的预期收益是多少?
根据华尔街分析师的预测,Virax Biolabs Group Ltd 的预期收益为 $
Virax Biolabs Group Ltd 是否超出收益预期?
Virax Biolabs Group Ltd 最近的收益为 $, 预期。
关键数据
前收盘价
$2.74
开盘价
$2.7
当日区间
$2.68 - $3.13
52周范围
$0.1 - $3.13
交易量
236.3K
平均成交量
21.5M
股息收益率
--
每股收益(TTM)
-1.25
市值
$62.3M
什么是 VRAX?
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).